Subtype
Hepatocellular Carcinoma
CI-CAN-00002853HCC · LIHCExplore in graph →
693 active trials13 approved drugs9 evidence items
Loading cancer entity…
Loading cancer entity…
Subtype
CI-CAN-00002853HCC · LIHCExplore in graph →
Clinical trials
3,126 studies whose conditions map to this entity or one of its descendants. Status and phase are as posted on ClinicalTrials.gov. 50 studies per page.
Computedformula ci-trial-intel-v1 · interventional studies · entity + NCIt descendants · hover a figure for its formulaCompare cancersTerminated studies (357)
| NCT | Title | Status | Phase | Enrollment (n) | Sponsor | Countries | Last update | Source |
|---|---|---|---|---|---|---|---|---|
| NCT07782632 | Liver Volume Metrics for Predicting Immunotherapy Prognosis in Unresectable Hepatocellular Carcinoma | recruiting | — | 467 | Anhui Provincial HospitalOTHER_GOV | 1 | Aug 24, 2026 | clinicaltrials |
| NCT03655002 | IRX-2, Cyclophosphamide, and Nivolumab in Treating Patients With Recurrent or Metastatic and Refractory Liver Cancer | active not recruiting | Phase 1 | 8 | City of Hope Medical CenterOTHER | 1 | Aug 21, 2026 |
| NCT07623369 | A First-in-Human Study of HH160 in Participants With Advanced or Metastatic Solid Tumors | recruiting | Phase 1 | 299 | Huahui HealthINDUSTRY | 2 | Aug 21, 2026 | clinicaltrials |
| NCT05269381 | Personalized Neoantigen Peptide-Based Vaccine in Combination With Pembrolizumab for Treatment of Advanced Solid Tumors(PNeoVCA) | recruiting | Phase 1 / Phase 2 | 138 | Mayo ClinicOTHER | 1 | Aug 20, 2026 | clinicaltrials |
| NCT05394259 | A Pilot Study to Assess the Clinical Utility of PYLARIFY PET-CT for Detecting Metastasis in Pancreatic Cancer, Hepatocellular Carcinoma and Breast Cancer | active not recruiting | Phase 1 | 20 | M.D. Anderson Cancer CenterOTHER | 1 | Aug 20, 2026 | clinicaltrials |
| NCT06166576 | Radioembolization as a Spearhead Treatment of Hepatocellular Carcinoma With Localized Portal Vein Tumor Thrombosis(RESOLVE) | recruiting | Phase 2 | 30 | Seoul National University HospitalOTHER | 1 | Aug 20, 2026 | clinicaltrials |
| NCT06178198 | Radiation Major Hepatectomy to Selectively Treat Large Unifocal Hepatocellular Carcinoma(RESCUE) | recruiting | Phase 2 | 30 | Seoul National University HospitalOTHER | 1 | Aug 20, 2026 | clinicaltrials |
| NCT06773845 | Building Evidence for Ablative Internal Radiation Therapy in Localized HCC Beyond the Up-To-7 Criteria(BEAT-UT7) | recruiting | Phase 2 | 100 | Seoul National University HospitalOTHER | 1 | Aug 20, 2026 | clinicaltrials |
| NCT07608458 | Scheduled Meditation for Improving Postoperative Outcomes in Patients Undergoing Pancreatectomy | not yet recruiting | N/A | 70 | City of Hope Medical CenterOTHER | 1 | Aug 20, 2026 | clinicaltrials |
| NCT06084884 | A Phase I/II Study to Evaluate AZD5851 in GPC3+ Advanced/Recurrent Hepatocellular Carcinoma(ATHENA) | active not recruiting | Phase 1 / Phase 2 | 94 | AstraZenecaINDUSTRY | 3 | Aug 19, 2026 | clinicaltrials |
| NCT07636785 | A Phase 1 and 2 Study of VMD-102 in Hepatocellular Carcinoma and Other Solid Tumors(SPKTAHC) | recruiting | Phase 1 / Phase 2 | 111 | VM Discovery, Inc.INDUSTRY | 1 | Aug 19, 2026 | clinicaltrials |
| NCT07774247 | Atezolizumab, Bevacizumab, and Tocilizumab in Advanced Hepatocellular Carcinoma(AB-TCZ) | not yet recruiting | Phase 2 | 51 | CHA UniversityOTHER | 1 | Aug 19, 2026 | clinicaltrials |
| NCT06764316 | A First-in-human Study to Learn About the Safety of BAY 3547926 and How Well it Works in Participants With Advanced Liver Cancer(BANTAM-01) | recruiting | Phase 1 | 148 | BayerINDUSTRY | 9 | Aug 18, 2026 | clinicaltrials |
| NCT06944483 | Same-day Radioembolization for Large HCC(ISTAR-01) | recruiting | — | 138 | Seoul National University HospitalOTHER | 1 | Aug 18, 2026 | clinicaltrials |
| NCT06979219 | Streamlining Radioembolization for Small HCC(ISTAR-02) | recruiting | — | 146 | Seoul National University HospitalOTHER | 1 | Aug 18, 2026 | clinicaltrials |
| NCT07620574 | Long-Term Extension Study for Participants Previously Enrolled in an Exelixis-Sponsored Study | enrolling by invitation | Phase 3 | 5,000 | ExelixisINDUSTRY | 1 | Aug 18, 2026 | clinicaltrials |
| NCT07727759 | CT Volumetry and Hepatic Vascular Deformation Mapping to Predict Post-Hepatectomy Liver Failure(BEYOND-SIZE) | recruiting | — | 1,070 | Minia UniversityOTHER | 1 | Aug 18, 2026 | clinicaltrials |
| NCT07166406 | Testing Immunotherapy With or Without Stereotactic Body Radiation Therapy in Patients With Advanced Liver Cancer, HELIO-RT Trial | recruiting | Phase 3 | 226 | NRG OncologyOTHER | 2 | Aug 17, 2026 | clinicaltrials |
| NCT07209813 | GKL-006 Injection Plus TACE Versus TACE Alone in Patients With Unresectable Hepatocellular Carcinoma | recruiting | Phase 2 | 48 | Beijing Gene Key Life Technology Co., LtdINDUSTRY | 1 | Aug 17, 2026 | clinicaltrials |
| NCT07768085 | Pragmatic RCT of AI-Assisted Reading for Malignant Hepatic Lesions on CE-CT | not yet recruiting | N/A | 40,000 | Shengjing HospitalOTHER | 1 | Aug 17, 2026 | clinicaltrials |
| NCT03847428 | Assess Efficacy and Safety of Durvalumab Alone or Combined With Bevacizumab in High Risk of Recurrence HCC Patients After Curative Treatment(EMERALD-2) | active not recruiting | Phase 3 | 908 | AstraZenecaINDUSTRY | 24 | Aug 14, 2026 | clinicaltrials |
| NCT04221893 | Radiation Therapy for the Treatment of Metastatic Gastrointestinal Cancers | recruiting | N/A | 28 | University of California, San FranciscoOTHER | 1 | Aug 14, 2026 | clinicaltrials |
| NCT04550481 | Role of Lisinopril in Preventing the Progression of Non-Alcoholic Fatty Liver Disease, RELIEF-NAFLD Study | active not recruiting | Phase 2 | 35 | Northwestern UniversityOTHER | 1 | Aug 14, 2026 | clinicaltrials |
| NCT07764835 | Prospective Evaluation of Hepatocellular Carcinoma Surveillance in At-Risk Patients (Screening HCC)(Screening HCC) | not yet recruiting | — | 300 | D'Or Institute for Research and EducationOTHER | 0 | Aug 14, 2026 | clinicaltrials |
| NCT05701488 | SIRT With Tremelimumab and Durvalumab for Resectable HCC | active not recruiting | Phase 1 | 20 | Jiping Wang, MD, PhDOTHER | 1 | Aug 13, 2026 | clinicaltrials |
| NCT06618300 | Streamlined Resin Y90 Radiation Segmentectomy for Small HCC(One&Done) | active not recruiting | — | 30 | UNC Lineberger Comprehensive Cancer CenterOTHER | 1 | Aug 13, 2026 | clinicaltrials |
| NCT06795022 | First in Human Study to Evaluate AZD9793 in Participants With Advanced or Metastatic Solid Tumours(RHEA-1) | recruiting | Phase 1 / Phase 2 | 304 | AstraZenecaINDUSTRY | 7 | Aug 13, 2026 | clinicaltrials |
| NCT04965454 | Evaluation of Treatment Predictors Reflecting Beta-catenin Activation in Hepatocellular Carcinoma(ExTRACT-HCC) | recruiting | Phase 2 | 80 | Queen's Medical CenterOTHER | 1 | Aug 12, 2026 | clinicaltrials |
| NCT06549829 | the Effect of Nutrition-optimized Prehabilitation on Perioperative Intervention in Primary Liver Carcinoma | recruiting | N/A | 120 | Second Affiliated Hospital, Zhejiang University, School of MedicineOTHER | 1 | Aug 12, 2026 | clinicaltrials |
| NCT07760012 | 68Ga-SorB PET/CT Imaging in Patients With Solid Tumors(SORB-PET) | recruiting | N/A | 50 | Peking University Third HospitalOTHER | 1 | Aug 12, 2026 | clinicaltrials |
| NCT07761286 | Evaluate the Safety and Efficacy of Combination Therapy With SYS6090 Injection for Hepatocellular Carcinoma | not yet recruiting | Phase 1 / Phase 2 | 288 | CSPC Megalith Biopharmaceutical Co.,Ltd.INDUSTRY | 1 | Aug 12, 2026 | clinicaltrials |
| NCT06242470 | A Study of MGC026 in Participants With Advanced Solid Tumors | recruiting | Phase 1 | 250 | MacroGenicsINDUSTRY | 3 | Aug 11, 2026 | clinicaltrials |
| NCT06880523 | STRIDE (Durvalumab + Tremelimumab) With Lenvatinib vs STRIDE Alone in Unresectable Hepatocellular Carcinoma(SLIDE-HCC) | recruiting | Phase 2 | 140 | Canadian Cancer Trials GroupNETWORK | 1 | Aug 11, 2026 | clinicaltrials |
| NCT06899152 | HepQuant: Study to Assess the Role of Blood-based Biomarkers and Quantitative MR Imaging for Patients Receiving Radiation Therapy for Liver Cancer(HepQuant) | recruiting | N/A | 40 | Montefiore Medical CenterOTHER | 1 | Aug 11, 2026 | clinicaltrials |
| NCT06904183 | Lenvatinib, Sintilimab, and DEB-TACE With/Without HAIC for HCC >7 cm With PVTT | recruiting | Phase 2 | 320 | Second Affiliated Hospital of Guangzhou Medical UniversityOTHER | 1 | Aug 11, 2026 | clinicaltrials |
| NCT03859128 | Toripalimab or Placebo as Adjuvant Therapy in Hepatocellular Carcinoma After Radical Resection(JUPITER 04) | active not recruiting | Phase 2 / Phase 3 | 427 | Shanghai Junshi Bioscience Co., Ltd.OTHER | 1 | Aug 10, 2026 | clinicaltrials |
| NCT03959800 | Molecular Basis of Pediatric Liver Cancer | recruiting | — | 1,600 | University of PittsburghOTHER | 1 | Aug 10, 2026 | clinicaltrials |
| NCT07159048 | The Safety, Efficacy, and Immune Response of Multimodal Thermal Therapy in the Treatment of Malignant Liver Tumors | recruiting | N/A | 120 | Fudan UniversityOTHER | 1 | Aug 10, 2026 | clinicaltrials |
| NCT07749859 | SHR-1701 Plus Apatinib for Second-Line Treatment in Targeted-Immune Pretreated Advanced Hepatocellular Carcinoma | not yet recruiting | Phase 2 | 80 | Cancer Institute and Hospital, Chinese Academy of Medical SciencesOTHER | 1 | Aug 6, 2026 | clinicaltrials |
| NCT02519348 | A Study of Durvalumab or Tremelimumab Monotherapy, or Durvalumab in Combination With Tremelimumab or Bevacizumab in Advanced Hepatocellular Carcinoma | active not recruiting | Phase 2 | 433 | MedImmune LLCINDUSTRY | 9 | Aug 5, 2026 | clinicaltrials |
| NCT05176483 | Study of Zanzalintinib in Combination With Immuno-Oncology or Other Agents in Participants With Solid Tumors(STELLAR-002) | recruiting | Phase 1 | 1,394 | ExelixisINDUSTRY | 13 | Aug 5, 2026 | clinicaltrials |
| NCT06910657 | IDOV-Immune for Advanced Solid Tumors | recruiting | Phase 1 | 78 | ViroMissile, Inc.INDUSTRY | 2 | Aug 5, 2026 | clinicaltrials |
| NCT07475026 | A Study of Neoadjuvant Tislelizumab Plus Lenvatinib in Resectable HCC at High Risk of Recurrence(Neo-LENTIS) | recruiting | Phase 3 | 198 | Tianjin Medical University Cancer Institute and HospitalOTHER | 1 | Aug 5, 2026 | clinicaltrials |
| NCT07748481 | Comparison of the Therapeutic Efficacy of Non-touch Microwave Ablation, Tumor-puncture Microwave Ablation and Surgical Resection for Subcapsular Hepatocellular Carcinoma | not yet recruiting | — | 180 | The First Hospital of Jilin UniversityOTHER | 0 | Aug 5, 2026 | clinicaltrials |
| NCT05168163 | Atezolizumab in Combination With a Multi-Kinase Inhibitor for the Treatment of Unresectable, Locally Advanced, or Metastatic Liver Cancer | recruiting | Phase 2 | 122 | Academic and Community Cancer Research UnitedOTHER | 1 | Aug 4, 2026 | clinicaltrials |
| NCT07381634 | The Safety and Efficacy of Ondansetron in Reducing Immune Checkpoint Inhibitor-Related Toxicities | recruiting | Phase 2 | 134 | First Affiliated Hospital of Wenzhou Medical UniversityOTHER | 1 | Aug 4, 2026 | clinicaltrials |
| NCT05443087 | TARGETed Therapy Drug MONITOring in DIGestive Oncology(TARGETMONITO) | recruiting | N/A | 330 | UNICANCEROTHER | 1 | Aug 3, 2026 | clinicaltrials |
| NCT06877637 | On-treatment Surveillance of Tumor Evolution and Response to Systemic Treatment in Bile Duct and Liver Cancer(BILLIONSTARS) | recruiting | — | 150 | Region SkaneOTHER | 1 | Aug 3, 2026 | clinicaltrials |
| NCT07179900 | Radiotherapy Combined With QL1706 and Bevacizumab for Unresectable Non-metastatic Hepatocellular Carcinoma | recruiting | Phase 2 | 60 | Hebei Medical University Fourth HospitalOTHER | 1 | Aug 3, 2026 | clinicaltrials |
Data updated 23 days agoSource updated Aug 24, 2026source: clinicaltrials